Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA

Journal of Clinical Virology

Volumn 58, Issue 2, 2013, Pages 401-407

  Martinot Peignoux, Michelle ^a   Lapalus, Martine ^a   Laouénan, Cédric ^a,c   Lada, Olivier ^a   Netto Cardoso, Ana Carolina Ferreira ^a   Boyer, Nathalie ^d   Ripault, Marie Pierre ^d   Carvalho Filho, Roberto ^a   Asselah, Tarik ^a,b,c,d   Marcellin, Patrick ^a,b,c,d  

^a CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔpital Bichat   (France)

^d BEAUJON HOSPITAL   (France)

Author keywords

ALT; HBV inactive carrier; HBV DNA; Prognosis; Viral hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE CARRIER; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; VIRAL CLEARANCE;

(PREVIOUS IL28B); AC; ACTIVE CARRIER; ALANINE AMINOTRANSFERASE; ALT; BASAL CORE PROMOTER; BCP; CHB; CHRONIC HEPATITIS B; HBEAG; HBSAG; HBV; HBV INACTIVE CARRIER; HBV-DNA; HCC; HEPATITIS B E ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VIRUS; HEPATOCELLULAR CARCINOMA; IC; IFN; IFNL3; INACTIVE CARRIER; INTERFERON; NEGATIVE PREDICTIVE VALUE; NPV; PC; POSITIVE PREDICTIVE VALUE; PPV; PRECORE; PROGNOSIS; REACTIVATION PATIENT; RP; VIRAL HEPATITIS;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ASYMPTOMATIC DISEASES; BIOLOGICAL MARKERS; CARRIER STATE; DNA; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SERUM; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84884531711     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2013.08.010     Document Type: Article

References (37)

1. McMahon B.J. The natural history of chronic hepatitis B virus infection. Hepatology 2009, 49(Suppl. 5):S45-S55. 10.1002/hep.22898.
2. Hoofnagle J.H. Chronic type B hepatitis. Gastroenterology 1983, 84:422-424.
3. Lok A.S., McMahon B.J. Chronic hepatitis B. Hepatology 2007, 45:507-539.
4. Carman W.F., Jacyna M.R., Hadziyannis S., et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989, 2:588-591.
5. Akahane Y., Yamanaka T., Suzuki H., et al. Chronic active hepatitis with hepatitis B virus DNA and antibody against e antigen in the serum. Disturbed synthesis and secretion of e antigen from hepatocytes due to a point mutation in the precore region. Gastroenterology 1990, 99:1113-1119.
6. Brunetto M.R., Stemler M., Shodel F., et al. Identification of HBV variants which cannot produce pre-core derived HBeAg and may be responsible for severe hepatitis. Ital J Gastroenterol 1989, 21:151-154.
7. Yotsuyanagi H., Hino K., Tomita E., et al. Precore and core promotor mutations, hepatitis B virus DNA levels and progressive liver injury in chronic hepatitis B. J Hepatol 2002, 37:355-363.
8. Brunetto M.R., Oliveri F., Coco B., et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002, 36:263-270.
9. Tai D.I., Lin S.M., Sheen I.S., et al. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology 2009, 49:1859-1867. 10.1002/hep.22878.
10. Sung J.J., Chan H.L., Wong M.L., et al. Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B virus-infected patients. J Viral Hepat 2002, 9:229-234.
11. Martinot-Peignoux M., Boyer N., Colombat M., et al. Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol 2002, 36:543-546.
12. Papatheodoridis G.V., Manolakopoulos S., Liaw Y.F., et al. Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. J Hepatol 2012, 57:196-202. (published online first: 23.03.12). 10.1016/j.jhep.2011.11.030.
13. Wursthorn K., Jaroszewicz J., Zacher B.J., et al. Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. J Clin Virol 2011, 50:292-296. (published online first: 26.01.11). 10.1016/j.jcv.2010.12.008.
14. Sonneveld M.J., Rijckborst V., Boucher C.A., et al. A comparison of two assays for quantification of Hepatitis B surface antigen in patients with chronic hepatitis B. J Clin Virol 2011, 51:175-178. (published online first: 17.05.11). 10.1016/j.jcv.2011.04.005.
15. Jia J.D., Hong M., Wei L., et al. Multicentre evaluation of the Elecsys hepatitis B surface antigen II assay for detection of HBsAg in comparison with other commercially available assays. Med Microbiol Immunol 2009, 198:263-269. (published online first: 16.10.09). 10.1007/s00430-009-0127-4.
16. Brunetto M.R., Moriconi F., Bonino F., et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009, 49:1141-1150. 10.1002/hep.22760.
17. Moucari R., Mackiewicz V., Lada O., et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009, 49:1151-1157. 10.1002/hep.22744.
18. Liaw Y.F. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology 2011, 53:2121-2129. 10.1002/hep.24364.
19. Chan H.L., Thompson A., Martinot-Peignoux M., et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol 2011, 55:1121-1131. (published online first: 28.06.11). 10.1016/j.jhep.2011.06.006.
20. Martinot-Peignoux M., Lapalus M., Asselah T., et al. HBsAg quantification: monitoring natural history and treatment outcome. Liver Int 2013, 33(Suppl. 1):125-132. 10.1111/liv.12075.
21. Nguyen T., Thompson A.J., Bowden S., et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010, 52:508-513. (published online first: 16.02.10). 10.1016/j.jhep.2010.01.007.
22. Jaroszewicz J., Calle Serrano B., Wursthorn K., et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010, 52:514-522. (published online first: 13.02.10). 10.1016/j.jhep.2010.01.014.
23. Kumar M., Chauhan R., Gupta N., et al. Spontaneous increases in alanine aminotransferase levels in asymptomatic chronic hepatitis B virus-infected patients. Gastroenterology 2009, 136:1272-1280. (published online first: 16.01.09). 10.1053/j.gastro.2009.01.011.
24. Brunetto M.R., Oliveri F., Colombatto P., et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010, 139:483-490. (published online first: 05.05.10). 10.1053/j.gastro.2010.04.052.
25. Lampertico P., Viganò M., Cheroni C., et al. IL28B polymorphisms predict interferon-related HBsAg seroclearance in genotype D HBeAg-negative patients with chronic hepatitis B. Hepatology 2013, 57:890-896. [published online first: 20 December 2012]. 10.1002/hep.25749.
26. Li W., Jiang Y., Jin Q., et al. Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver Int 2011, 31:1118-1126. (published online first: 30.06.11). 10.1111/j. 1478-3231.2011.02507.x.
27. Hsu Y.S., Chien R.N., Yeh C.T., et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002, 35:1522-1527.
28. Chu C.M., Liaw Y.F. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology 2007, 133:1458-1465. (published online first: 21.08.07).
29. Chu C.M., Liaw Y.F. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007, 45:1187-1192.
30. Chan H.L., Wong V.W., Wong G.L., et al. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010, 52:1232-1241. 10.1002/hep.23803.
31. Chen J.D., Yang H.I., Iloeje U.H., et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related disease. Gastroenterology 2010, 138:1747-1754. (published online first: 28.01.10). 10.1053/j.gastro.2010.01.042.
32. Tseng T.C., Liu C.J., Yang H.C., et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology 2013, 57:441-450. [published online first: 6 December 2012]. 10.1002/hep.26041.
33. Tseng T.C., Liu C.J., Su T.H., et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011, 141:517-525. (published online first: 28.04.11). 10.1053/j.gastro.2011.04.046.
34. Chu C.M., Genotype Liaw Y.F. C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol 2005, 43:411-417.
35. Chan H.L., Wong G.L., Tse C.H., et al. Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. J Infect Dis 2011, 204:408-414. 10.1093/infdis/jir283.
36. Liu J., Lee M.H., Batrla-Utermann R., et al. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. J Hepatol online first 2012, (pii: S0168-8278(12)00954-3, http://dx.doi.org/10.1016/j.jhep.2012.12.006, Online first: 13.12.12).
37. Martin M.P., Qi Y., Goedert J.J., et al. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis 2010, 202:1749-1753. (published online first: 26.10.10). 10.1086/657146.